This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adams, J. Search for Related Content PubMed PubMed Citation Articles by Adams, J.

Development of the Proteasome Inhibitor PS-341

Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA

Correspondence: Julian Adams, Ph.D., Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, Massachusetts 02139, USA. Telephone: 617-551-3674; Fax: 617-679-7370; e-mail: jadams{at}mpi.com

Over the last decade, the critical role of the proteasome in cell-cycle regulation has become increasingly apparent. The proteasome, a multicatalytic protease present in all eukaryotic cells, is the primary component of the protein degradation pathway of the cell. By degrading regulatory proteins (or their inhibitors), the proteasome serves as a central conduit for many cellular regulatory signals and, thus, is a novel target for therapeutic drugs. PS-341 is a small molecule that is a potent and selective inhibitor of the proteasome. In vitro and mouse xenograft studies of PS-341 have shown antitumor activity in a variety of tumor types, including myeloma, chronic lymphocytic leukemia, prostate cancer, pancreatic cancer, and colon cancer, among others. Although PS-341 rapidly leaves the vascular compartment, a novel pharmacodynamic assay has shown that inhibition of proteasome—the biologic target—is dose dependent and reversible. These studies provided the rationale for a twice-weekly dosing schedule employed in ongoing clinical studies. Phase I trials in a variety of tumor types have shown PS-341 to be well tolerated, and phase II trials in several hematologic malignancies and solid tumor types are now in progress. Efficacy and safety data from the most advanced of these, a phase II multicenter trial in myeloma, will be available in early 2002.

Key Words. Antineoplastic agents • Boronic acids • Enzyme inhibitors (administration and dose) • NF-B (antagonists and inhibitors) • Hematologic neoplasms (drug therapy) • Multienzyme complexes (antagonists and inhibitors) • 26S Proteasome • Multiple myeloma

This article has been cited by other articles:

				A. Marten, N. Zeiss, S. Serba, S. Mehrle, M. von Lilienfeld-Toal, and J. Schmidt Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma Mol. Cancer Ther., November 1, 2008; 7(11): 3624 - 3631. [Abstract] [Full Text] [PDF]

				G. Gao, J. Zhang, X. Si, J. Wong, C. Cheung, B. McManus, and H. Luo Proteasome inhibition attenuates coxsackievirus-induced myocardial damage in mice Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H401 - H408. [Abstract] [Full Text] [PDF]

				W. Bensinger Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492. [Abstract] [Full Text] [PDF]

				L. Li, C. S. Gondi, D. H. Dinh, W. C. Olivero, M. Gujrati, and J. S. Rao Transfection with Anti-p65 Intrabody Suppresses Invasion and Angiogenesis in Glioma Cells by Blocking Nuclear Factor-{kappa}B Transcriptional Activity Clin. Cancer Res., April 1, 2007; 13(7): 2178 - 2190. [Abstract] [Full Text] [PDF]

				R. Dreicer, D. Petrylak, D. Agus, I. Webb, and B. Roth Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1208 - 1215. [Abstract] [Full Text] [PDF]

				M.-V. Mateos, J.-M. Hernandez, M.-T. Hernandez, N.-C. Gutierrez, L. Palomera, M. Fuertes, J. Diaz-Mediavilla, J.-J. Lahuerta, J. de la Rubia, M.-J. Terol, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study Blood, October 1, 2006; 108(7): 2165 - 2172. [Abstract] [Full Text] [PDF]

				F. Teraishi, W. Guo, L. Zhang, F. Dong, J. J. Davis, T. Sasazuki, S. Shirasawa, J. Liu, and B. Fang Activation of Sterile20-Like Kinase 1 in Proteasome Inhibitor Bortezomib-Induced Apoptosis in Oncogenic K-ras-Transformed Cells. Cancer Res., June 15, 2006; 66(12): 6072 - 6079. [Abstract] [Full Text] [PDF]

				C Kersting, J Packeisen, B Leidinger, B Brandt, R von Wasielewski, W Winkelmann, P J van Diest, G Gosheger, and H Buerger Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas J. Clin. Pathol., June 1, 2006; 59(6): 585 - 590. [Abstract] [Full Text] [PDF]

				J. A. Sosman and I. Puzanov Molecular targets in melanoma from angiogenesis to apoptosis. Clin. Cancer Res., April 1, 2006; 12(7): 2376s - 2383s. [Abstract] [Full Text] [PDF]

				B. C. Beehler, P. G. Sleph, L. Benmassaoud, and G. J. Grover Reduction of Skeletal Muscle Atrophy by a Proteasome Inhibitor in a Rat Model of Denervation Exp Biol Med, March 1, 2006; 231(3): 335 - 341. [Abstract] [Full Text] [PDF]

				B. Dublet, A. Ruello, M. Pederzoli, E. Hajjar, M. Courbebaisse, S. Canteloup, N. Reuter, and V. Witko-Sarsat Cleavage of p21/WAF1/CIP1 by Proteinase 3 Modulates Differentiation of a Monocytic Cell Line: MOLECULAR ANALYSIS OF THE CLEAVAGE SITE J. Biol. Chem., August 26, 2005; 280(34): 30242 - 30253. [Abstract] [Full Text] [PDF]

				Y. Dai, M. Rahmani, X.-Y. Pei, P. Dent, and S. Grant Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms Blood, July 15, 2004; 104(2): 509 - 518. [Abstract] [Full Text] [PDF]

				C. E. Denlinger, M. D. Keller, M. W. Mayo, R. M. Broad, and D. R. Jones Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1078 - 1086. [Abstract] [Full Text] [PDF]

				G. Helbig, K. W. Christopherson II, P. Bhat-Nakshatri, S. Kumar, H. Kishimoto, K. D. Miller, H. E. Broxmeyer, and H. Nakshatri NF-{kappa} B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4 J. Biol. Chem., June 6, 2003; 278(24): 21631 - 21638. [Abstract] [Full Text] [PDF]

				A. V. Lee, R. Schiff, X. Cui, D. Sachdev, D. Yee, A. P. Gilmore, C. H. Streuli, S. Oesterreich, and D. L. Hadsell New Mechanisms of Signal Transduction Inhibitor Action: Receptor Tyrosine Kinase Down-Regulation and Blockade of Signal Transactivation Clin. Cancer Res., January 1, 2003; 9(1): 516s - 523s. [Abstract] [Full Text]

				J. Baselga Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy Oncologist, August 15, 2002; 7(90004): 2 - 8. [Abstract] [Full Text] [PDF]